UK's BioFocus sees turnover triple in 2000
UK-based specialist chemistry company BioFocus has reported turnover ofL5.6 million ($8.1 million ) for 2000, more than triple the L1.7 million booked in 1999, in its preliminary results for the year ended December 31, 2000. Profit before tax was L1.4 million, compared to L90,000 in 1999.
The company noted that the strong results were driven by demand for its SoftFocus targeted compound libraries. At year-end, BioFocus' net cash balance stood at L3.9 million, and the company notes that "this will provide the base for expansion of our core business and the addition of complementary services."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze